222 related articles for article (PubMed ID: 16607925)
1. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
Aycan Z; Ocal G; Berberoglu M; Cetinkaya E; Adiyaman P; Evliyaoglu O
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):245-51. PubMed ID: 16607925
[TBL] [Abstract][Full Text] [Related]
2. Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency).
Gasparini N; Di Maio S; Salerno M; Argenziano A; Franzese A; Tenore A
Horm Res; 1997; 47(1):17-22. PubMed ID: 9010713
[TBL] [Abstract][Full Text] [Related]
3. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone.
Bonfig W; Schmidt H; Schwarz HP
Horm Res Paediatr; 2011; 75(1):32-7. PubMed ID: 20714115
[TBL] [Abstract][Full Text] [Related]
4. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM; Simm D; Beier C; Dörr HG
Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
[TBL] [Abstract][Full Text] [Related]
5. Long-term Growth in Congenital Adrenal Hyperplasia.
Maheshwari A; Khadilkar V; Gangodkar P; Khadilkar A
Indian J Pediatr; 2019 Feb; 86(2):154-158. PubMed ID: 30097840
[TBL] [Abstract][Full Text] [Related]
6. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
Bonfig W; Schwarz HP
Horm Res Paediatr; 2011; 75(4):264-8. PubMed ID: 21196707
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
Pijnenburg-Kleizen KJ; Thomas CMG; Otten BJ; Roeleveld N; Claahsen-van der Grinten HL
J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1055-1063. PubMed ID: 31573958
[TBL] [Abstract][Full Text] [Related]
8. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
Bizzarri C; Improda N; Maggioli C; Capalbo D; Roma S; Porzio O; Salerno M; Cappa M
Endocr Pract; 2017 May; 23(5):546-556. PubMed ID: 28225306
[TBL] [Abstract][Full Text] [Related]
9. Final height of patients with classical congenital adrenal hyperplasia.
Aycan Z; Akbuğa S; Cetinkaya E; Ocal G; Berberoğlu M; Evliyaoğlu O; Adiyaman P
Turk J Pediatr; 2009; 51(6):539-44. PubMed ID: 20196386
[TBL] [Abstract][Full Text] [Related]
10. Long-term prednisone versus hydrocortisone treatment in children with classic Congenital Adrenal Hyperplasia (CAH) and a brief review of the literature.
Ahmed SEAM; Soliman AT; Ramadan MA; Elawwa A; Abugabal AMS; Emam MHA; De Sanctis V
Acta Biomed; 2019 Sep; 90(3):360-369. PubMed ID: 31580328
[TBL] [Abstract][Full Text] [Related]
11. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience.
Hoepffner W; Kaufhold A; Willgerodt H; Keller E
Horm Res; 2008; 70(1):42-50. PubMed ID: 18493149
[TBL] [Abstract][Full Text] [Related]
12. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W; Bechtold S; Schmidt H; Knorr D; Schwarz HP
J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
[TBL] [Abstract][Full Text] [Related]
13. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Hauffa BP; Winter A; Stolecke H
Klin Padiatr; 1997; 209(2):71-7. PubMed ID: 9113619
[TBL] [Abstract][Full Text] [Related]
14. Monitoring treatment in congenital adrenal hyperplasia.
Appan S; Hindmarsh PC; Brook CG
Arch Dis Child; 1989 Sep; 64(9):1235-9. PubMed ID: 2640553
[TBL] [Abstract][Full Text] [Related]
15. Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia.
Silva IN; Kater CE; Cunha CF; Viana MB
Arch Dis Child; 1997 Sep; 77(3):214-8. PubMed ID: 9370898
[TBL] [Abstract][Full Text] [Related]
16. The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia.
Cetinkaya S; Kara C
J Pediatr Endocrinol Metab; 2011; 24(5-6):265-9. PubMed ID: 21823521
[TBL] [Abstract][Full Text] [Related]
17. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
Manoli I; Kanaka-Gantenbein Ch; Voutetakis A; Maniati-Christidi M; Dacou-Voutetakis C
Clin Endocrinol (Oxf); 2002 Nov; 57(5):669-76. PubMed ID: 12390343
[TBL] [Abstract][Full Text] [Related]
18. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia.
Ciaccio M; Montiveros C; Rivarola MA; Belgorosky A
Medicina (B Aires); 2002; 62(6):551-4. PubMed ID: 12532689
[TBL] [Abstract][Full Text] [Related]
19. Effect of treatment on growth in congenital adrenal hyperplasia.
Ercan O; Hatemi S; Kutlu E; Turan N
Indian J Pediatr; 2000 Nov; 67(11):783-9. PubMed ID: 11216375
[TBL] [Abstract][Full Text] [Related]
20. 17-Hydroxyprogesterone rhythms and growth velocity in congenital adrenal hyperplasia.
Pincus DR; Kelnar CJ; Wallace AM
J Paediatr Child Health; 1993 Aug; 29(4):302-4. PubMed ID: 8373678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
